Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies

Study Overview
=================
Brief Summary
-----------------
Justification: We have recently demonstrated that maternofetal alloimmunization was not limited to blood cells: maternal alloimmunization against a glomerular podocyte antigen expressed by the placenta can induce neonatal membranous glomerulonephritis. Early recurrent pregnancy losses, preeclampsia and intervillositis are obstetrical pathologies which share an anomaly of placentation. Pathophysiology of these diseases is not yet fully understood; nevertheless the hypothesis of an incompatibility between mother and child is often mentioned. The aim of this project is to detect and study the cases of recurrent pregnancy losses, preeclamspia and intervillositis which could be induced by tissular maternofetal alloimmunization. Materials and methods: Patients suffering from recurrent pregnancy losses of unknown origin, preeclamspia or intervillositis will be included in this project. Mothers' sera will be studied by indirect immunofluorescence and Western Blot on placental biopsies from different origins and gestational ages. This stage will enable us to detect possible maternal allo-antibodies. After detecting and revealing antibodies, nature of the target antigen will be identified by immunoprecipitation of placental extracts, using the positive sera. Immunoprecipitation will be followed by a mass spectrometry analysis of detected proteins. Expected results: This study will enable us: to detect new cases of tissular maternofetal alloimmunization to improve our knowledge of mechanisms leading to anomalies of placentation to carry out a specific, preventive therapeutic approach for cases induced by tissular alloimmunization. Key words: Recurrent pregnancy losses, Preeclampsia, Intervillositis, maternofetal alloimmunization.

Official Title
-----------------
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies

Conditions
-----------------
Recurrent Pregnancy Losses, Preeclampsia, Intervillositis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recurrent pregnancy losses : patient having or having suffered from at least 3 consecutive, unexplained recurrent pregnancy losses, during the first 3 months of pregnancy, with the same paerson/man. Preeclampsia : blood pressure > 140/90 mm Hg ; proteinuria > 0,3 g/ 24 h Intervillositis : patient suffering or having suffered from intervillositis Exclusion Criteria: Recurrent pregnancy losses : uterine pathology, endocrine pathology, autoimmune pathology, coagulation and hemostasis pathology, karyotype anomaly. Preeclampsia : pre-existing high blood pressure, pre-existing diabetes, pre-existing renal disease, antiphospholipid antibodies syndrome Intervillositis : intervillositis with villositis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| repeated miscarriages<br>60 womens for repeated miscarriages will be included | |
| Preeclampsia<br>70 women for pre-eclampsia will be included | |
| intervillites<br>20 women for intervillites will be included | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
preeclampsia, recurrent pregnancy losses, intervillositis, maternofetal alloimmunization